Philip Bejon

Research interests

Publications

• Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

  The Lancet · 2024 · 10.1016/s0140-6736(23)02511-4

• An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples

  Wellcome Open Research · 2021 · 10.12688/wellcomeopenres.16168.1

• Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans

  Cell Reports · 2021 · 10.1016/j.celrep.2020.108684

• Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors

  Science · 2020 · 10.1126/science.abe1916

• Oral versus Intravenous Antibiotics for Bone and Joint Infection

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1710926

• Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis

  The Lancet Global Health · 2019 · 10.1016/s2214-109x(19)30457-7

• Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity

  Nature Communications · 2017 · 10.1038/s41467-017-01270-4

• Genetic diversity of the African malaria vector Anopheles gambiae

  Nature · 2017 · 10.1038/nature24995

• The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900

  Nature · 2017 · 10.1038/nature24059

• Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1515257

• Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1502924

• A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens

  Nature · 2015 · 10.1038/nature16450

• Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1505819

• Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

  The Lancet Infectious Diseases · 2015 · 10.1016/s1473-3099(15)00239-x

• The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection

  PLoS ONE · 2013 · 10.1371/journal.pone.0061395

• Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1207564

• Chronic Exposure to Plasmodium falciparum Is Associated with Phenotypic Evidence of B and T Cell Exhaustion

  The Journal of Immunology · 2012 · 10.4049/jimmunol.1202438

• Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

  The Lancet Infectious Diseases · 2011 · 10.1016/s1473-3099(10)70262-0

• Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya

  PLoS Medicine · 2010 · 10.1371/journal.pmed.1000304

• Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology

  Journal of Antimicrobial Chemotherapy · 2010 · 10.1093/jac/dkp469

• HIV Infection, Malnutrition, and Invasive Bacterial Infection among Children with Severe Malaria

  Clinical Infectious Diseases · 2009 · 10.1086/600299

• One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome

  Journal of Antimicrobial Chemotherapy · 2009 · 10.1093/jac/dkp107

• Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0807381

• Upregulation of TGF-β, FOXP3, and CD4+CD25+ Regulatory T Cells Correlates with More Rapid Parasite Growth in Human Malaria Infection

  Immunity · 2005 · 10.1016/j.immuni.2005.08.006

• Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

  Proceedings of the National Academy of Sciences · 2005 · 10.1073/pnas.0406381102

Current projects

No projects listed.